John Connolly has a new mission to tack on to his role at the Parker Institute: interim chief of a buzzy biotech backed by a pair of billionaires
John Connolly, the new chief scientist at the Parker Institute for Cancer Immunotherapy, has a fresh mission on his plate.
Connolly’s been tapped to take the interim CEO spot at 3T Biosciences, a buzzy Bay Area startup that’s joined the whole cell therapy 2.0 movement with the help of 2 tech billionaires who have shown a big interest in cancer drug development: Peter Thiel and Sean Parker, who lent his name and direct involvement to his eponymous nonprofit.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.